VRTX Vertex Pharmaceuticals PE ratio, current and historical analysis
The current PE ratio of VRTX cannot be calculated, as the latest EPS of -$1.85 is negative. Vertex Pharmaceuticals's last PE ratio on record was 26.83 in March 2024.
VRTX PE ratio history
The mean historical PE ratio of Vertex Pharmaceuticals over the last eight years is 53.28. Analyzing the last eight years, VRTX's PE ratio reached its highest point in the Sep 2017 quarter at 190.05, with a price of $152.04 and an EPS of $0.8. The Dec 2018 quarter saw the lowest point at 20.11, with a price of $165.71 and an EPS of $8.24.
Vertex Pharmaceuticals PE ratio by year
Maximum annual increase: 137.74% in 2019
Maximum annual decrease: -85.78% in 2018
| Year | PE ratio | Change |
|---|---|---|
| 2023 | 28.96 | 30.04% |
| 2022 | 22.27 | -7.82% |
| 2021 | 24.16 | 6.71% |
| 2020 | 22.64 | -52.65% |
| 2019 | 47.81 | 137.74% |
| 2018 | 20.11 | -85.78% |
| 2017 | 141.38 | N/A |
| 2016 | N/A | N/A |
| 2015 | N/A | N/A |
| 2014 | N/A | N/A |
VRTX average PE ratio chart
VRTX PE vs peers
| Stock name | PE ratio | Market cap |
|---|---|---|
| MRK Merck & Co Inc | 20.85 | $252.61B |
| JNJ Johnson & Johnson | 25.79 | $374.39B |
| ABBV AbbVie Inc | 59.63 | $303.47B |
| GILD Gilead Sciences Inc | 897.6 | $111.86B |
| BMY Bristol Myers Squibb Co | N/A | $118.1B |
| ENTA Enanta Pharmaceuticals Inc | N/A | $197.27M |
| VRTX Vertex Pharmaceuticals Inc | N/A | $115.98B |
Frequently asked questions
What is Vertex Pharmaceuticals's PE ratio?
The current price to earnings ratio of VRTX cannot be determined, as its EPS of -$1.85 is negative.
What is the 3-year average PE ratio for Vertex Pharmaceuticals (VRTX)?
Over the last 3 years, the average PE ratio for VRTX stock is 25.22.
What is the 5-year average PE ratio for Vertex Pharmaceuticals (VRTX)?
Over the last 5 years, the average PE ratio for VRTX stock is 27.44.
What is the highest PE ratio for VRTX?
The highest quarterly PE ratio in the last eight years has been 190.05 and it was in the Sep 2017 quarter.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from 
and Sharadar.